Explore 130+ historical metrics & ratios
Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Toyobo Co., Ltd. is a diversified Japanese specialty chemicals and advanced materials manufacturer operating across films, functional polymers, life sciences, and industrial textiles. The company produces high-performance polyester films for electronics and packaging, engineering plastics for automotive applications, bio-pharmaceuticals including enzymes and diagnostic reagents, and technical textiles for airbags and industrial use. With 23% gross margins and 3.9% operating margins, Toyobo operates in capital-intensive segments with moderate pricing power, facing pressure from Asian competitors and cyclical end-market demand.
Toyobo generates revenue through manufacturing and selling differentiated specialty materials with technical specifications that command moderate premiums over commodity alternatives. The films business serves electronics OEMs with optical-grade polyester films requiring precise thickness control and optical properties. Life sciences operates on contract manufacturing margins (15-25%) and proprietary enzyme sales. Industrial textiles benefit from long-term supply agreements with automotive OEMs for airbag fabrics, providing stable volumes but limited pricing flexibility. Pricing power is constrained by competition from Korean and Chinese producers in films, while life sciences enjoys better margins through IP-protected products. The business model requires continuous capex (¥45.2B annually) to maintain production efficiency and develop next-generation materials.
Yen/USD exchange rate movements affecting export competitiveness and translated overseas earnings (estimated 20-30% of revenue from exports)
Capacity utilization rates in films segment driven by electronics demand cycles (smartphones, displays, automotive electronics)
Raw material cost fluctuations, particularly crude oil derivatives (paraxylene, MEG) impacting polyester production economics
Life sciences contract wins and bio-pharmaceutical production volumes, particularly enzyme sales to industrial customers
Automotive production volumes in Japan and Asia affecting airbag fabric demand and engineering plastics sales
Commoditization of polyester films as Chinese producers expand capacity with government subsidies, compressing margins and market share in standard-grade products
Technological disruption in display technologies (OLED, microLED) potentially reducing demand for traditional polyester optical films used in LCD backlights
Aging Japanese domestic market and declining automotive production in home market requiring greater international expansion into competitive markets
Environmental regulations increasing costs for petrochemical-based production and requiring investment in bio-based alternatives or carbon capture
Korean competitors (SKC, Kolon Industries) and Chinese producers (Jiangsu Shuangxing, Polyplex) offering lower-cost polyester films with improving quality
Global pharmaceutical companies vertically integrating enzyme production, reducing contract manufacturing opportunities in life sciences segment
Automotive OEMs pressuring suppliers for annual cost reductions (typically 2-3% annually) on airbag fabrics and engineering plastics
Elevated capex intensity (¥45.2B annually vs ¥30.1B operating cash flow) creating negative free cash flow of ¥15.1B, requiring debt financing or asset sales
Debt/equity ratio of 1.27 limiting financial flexibility for acquisitions or counter-cyclical investments, with interest coverage estimated at 4-5x
Low ROE of 4.6% and ROA of 1.5% indicating capital allocation challenges and potential impairment risks on underperforming assets
Pension obligations common to Japanese industrial companies potentially requiring additional funding if equity markets decline or interest rates remain low
high - Films and industrial materials segments are directly tied to industrial production cycles, particularly electronics manufacturing and automotive production. Electronics demand (smartphones, displays, laptops) drives polyester film volumes, while automotive production affects airbag fabric and engineering plastics. Life sciences provides partial counter-cyclicality through pharmaceutical demand, but represents only 25-30% of revenue. Operating leverage amplifies margin swings during demand cycles, with 10% volume changes potentially impacting operating margins by 100-150 basis points given high fixed cost base.
Moderate sensitivity through financing costs on ¥1.27 debt/equity ratio, with estimated net debt around ¥75-85B. Rising Japanese interest rates (currently near-zero but normalizing) would increase interest expense by ¥750M-850M per 100bps rate increase. Additionally, higher global rates strengthen USD/JPY, benefiting export competitiveness but increasing imported raw material costs. Valuation multiples compress with rising rates given low ROE (4.6%) and modest growth profile (1.9% revenue growth).
Moderate - Customer credit quality matters for contract manufacturing and B2B sales, but diversified customer base across electronics OEMs, pharmaceutical companies, and automotive suppliers limits concentration risk. Working capital cycles extend during economic slowdowns as customers delay payments, impacting cash conversion. No significant consumer credit exposure. Supplier financing for raw materials (petrochemicals) operates on standard 30-60 day terms.
value - Trading at 0.3x price/sales and 0.7x price/book with 9.0x EV/EBITDA suggests deep value orientation. Low ROE (4.6%) and negative FCF deter growth investors. Flat recent performance (0% returns across 3/6/12 months) indicates lack of momentum. Attracts Japanese value investors, contrarian investors betting on restructuring or cyclical recovery, and special situations investors focused on potential asset sales or business unit spin-offs. Not suitable for growth, momentum, or income investors given modest growth, stagnant price action, and likely low dividend yield.
moderate - As a diversified Japanese industrial with global operations, volatility driven by yen fluctuations, commodity price swings, and electronics demand cycles. Beta likely 0.9-1.1 relative to Japanese equity markets. Lower volatility than pure-play chemical companies due to life sciences diversification, but higher than defensive consumer staples. Liquidity constraints from small market cap (¥0.6B) may amplify price swings on modest volume.